| scholarly article | Q13442814 |
| P2093 | author name string | Issam I Raad | |
| Roy F Chemaly | |||
| Ray Hachem | |||
| Javier A Adachi | |||
| Frank Tverdek | |||
| Jharna N Shah | |||
| Kenneth V Rolston | |||
| Sminil N Mahajan | |||
| Victor Mulanovich | |||
| P2860 | cites work | Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America | Q33688646 |
| Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children | Q34157657 | ||
| The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections | Q34330270 | ||
| Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus | Q34558111 | ||
| Predicting high vancomycin minimum inhibitory concentration in methicillin-resistant Staphylococcus aureus bloodstream infections | Q34756833 | ||
| Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia | Q34783668 | ||
| Linezolid vs glycopeptide antibiotics for the treatment of suspected methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a meta-analysis of randomized controlled trials | Q34923394 | ||
| Potential impact of vancomycin pulmonary distribution on treatment outcomes in patients with methicillin-resistant Staphylococcus aureus pneumonia | Q36428418 | ||
| Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin | Q36870858 | ||
| A European survey of antibiotic management of methicillin-resistant Staphylococcus aureus infection: current clinical opinion and practice | Q37707478 | ||
| Management of serious meticillin-resistant Staphylococcus aureus infections: what are the limits? | Q37837241 | ||
| Prospective study of 114 consecutive episodes of Staphylococcus aureus bacteremia. | Q39681835 | ||
| Panton Valentine Leukocidin exotoxin has no effect on the outcome of cancer patients with methicillin-resistant Staphylococcus aureus (MRSA) infections | Q40314403 | ||
| Efficacy of usual and high doses of daptomycin in combination with rifampin versus alternative therapies in experimental foreign-body infection by methicillin-resistant Staphylococcus aureus. | Q42036509 | ||
| Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years | Q43117809 | ||
| Staphylococcus aureus sepsis in hospitalized non neutropenic patients: retrospective clinical and microbiological analysis | Q43620522 | ||
| Methicillin-resistant Staphylococcus aureus bacteremia: epidemiology, outcome, and laboratory characteristics in a tertiary referral center in the UK. | Q43670473 | ||
| Treatment and outcome of Staphylococcus aureus bacteremia: a prospective study of 278 cases | Q43849799 | ||
| Staphylococcus aureus bacteremia in patients with hematological malignancies and/or agranulocytosis | Q43877429 | ||
| Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy | Q44959085 | ||
| High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity | Q45302930 | ||
| Efficacy of daptomycin combined with rifampicin for the treatment of experimental meticillin-resistant Staphylococcus aureus (MRSA) acute osteomyelitis | Q45579971 | ||
| Clinical features and outcomes of Staphylococcus aureus infections in non-neutropenic cancer patients. | Q45908851 | ||
| Risk factors for mortality caused by Staphylococcus aureus bacteremia in cancer patients. | Q46554540 | ||
| Characteristics and outcomes of methicillin-resistant Staphylococcus aureus surgical-site infections in patients with cancer: a case-control study | Q46674202 | ||
| Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia | Q46826194 | ||
| Microbiological effects of prior vancomycin use in patients with methicillin-resistant Staphylococcus aureus bacteraemia. | Q46879391 | ||
| Staphylococcus aureus bacteremia: a 14-year nationwide study in hematological patients with malignant disease or agranulocytosis. | Q51025866 | ||
| Outcome of Staphylococcus aureus bacteremia according to compliance with recommendations of infectious diseases specialists: experience with 244 patients. | Q52234767 | ||
| Pathogenic significance of methicillin resistance for patients with Staphylococcus aureus bacteremia. | Q54062872 | ||
| National Nosocomial Infections Surveillance (NNIS) report, data summary from October 1986-April 1996, issued May 1996. A report from the National Nosocomial Infections Surveillance (NNIS) System | Q56898992 | ||
| Antibiotic Choice May Not Explain Poorer Outcomes in Patients With Staphylococcus aureus Bacteremia and High Vancomycin Minimum Inhibitory Concentrations | Q57763234 | ||
| Nosocomial and community-acquired Staphylococcus aureus bacteremias from 1980 to 1993: impact of intravascular devices and methicillin resistance | Q71616583 | ||
| Predisposing factors and outcome of Staphylococcus aureus bacteremia in neutropenic patients with cancer | Q73761370 | ||
| Efficacy and safety of linezolid in immunocompromised children with cancer | Q82867281 | ||
| Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets | Q83770914 | ||
| Vancomycin minimum inhibitory concentration and outcome in patients with Staphylococcus aureus bacteremia: pearl or pellet? | Q84531634 | ||
| Clinical characteristics of vancomycin minimum inhibitory concentration of 2 μg/ml methicillin-resistant Staphylococcus aureus strains isolated from patients with bacteremia | Q84563829 | ||
| P433 | issue | 10 | |
| P921 | main subject | Staphylococcus aureus | Q188121 |
| vancomycin | Q424027 | ||
| methicillin-resistant Staphylococcus aureus | Q595158 | ||
| P304 | page(s) | 1329-1336 | |
| P577 | publication date | 2012-06-15 | |
| P1433 | published in | Oncologist | Q2122327 |
| P1476 | title | Characteristics and outcomes of methicillin-resistant staphylococcus aureus bloodstream infections in patients with cancer treated with vancomycin: 9-year experience at a comprehensive cancer center | |
| P478 | volume | 17 |
| Q38212258 | Antibiotic resistance in cancer patients. |
| Q54293201 | Antimicrobial activity of oritavancin and comparator agents when tested against Gram-positive bacterial isolates causing infections in cancer patients (2014-16). |
| Q89285166 | Bloodstream infection caused by S. aureus in patients with cancer: a 10-year longitudinal single-center study |
| Q98612843 | Ceftobiprole for Treatment of MRSA Blood Stream Infection: A Case Series |
| Q34726054 | Current Microbiology of Surgical Site Infections in Patients with Cancer: A Retrospective Review |
| Q42249906 | Daptomycin use in neutropenic patients with documented gram-positive infections |
| Q61800856 | GPER activation protects against epithelial barrier disruption by Staphylococcus aureus α-toxin |
| Q40252885 | In vitro activity of dalbavancin and five comparator agents against common and uncommon Gram-positive organisms isolated from cancer patients |
| Q42215430 | In vitro activity of telavancin compared with vancomycin and linezolid against Gram-positive organisms isolated from cancer patients |
| Q34999884 | Invasive gram-positive bacterial infection in cancer patients |
| Q36856946 | Is it time to replace vancomycin in the treatment of methicillin-resistant Staphylococcus aureus infections? |
| Q38749061 | Optimizing Symptoms and Management of Febrile Neutropenia among Cancer Patients: Current Status and Future Directions |
| Q38613929 | The challenge of antibiotic resistance in haematology patients |
| Q37347361 | The effect of age and weight on vancomycin serum trough concentrations in pediatric patients |
| Q40706134 | The emerging problem of bacterial resistance in cancer patients; proceedings of a workshop held by MASCC "Neutropenia, Infection and Myelosuppression" Study Group during the MASCC annual meeting held in Berlin on 27-29 June 2013. |
| Q34596203 | Vaccine protection of leukopenic mice against Staphylococcus aureus bloodstream infection |
| Q41158049 | Vancomycin pharmacokinetics and predicted dosage requirements in pediatric cancer patients |
Search more.